Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Expands Approval Of Breast Cancer Drug Kisqali
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
Anti-fibrotic drug shows promise in breast cancer
The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of HER2-negative cancers varies among patients,
FDA expanded their approval on drug cancer drug
First News
Insight News
1h
Breast density and mammograms: New FDA rule will ensure all women have more information after cancer screenings
The Food and Drug Administration implemented a rule to go into effect on Sept. 10, 2024, requiring mammography facilities to notify women about their breast density. The goal is to ...
3h
FDA’s new mandate shifts what patients should know about breast density
Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Kentucky judge fatally shot
$230 million crypto theft
Secret Service probing post
Boy kills bear, saves father
FCC chair denies Trump call
Cancels appearance w/ Duda
Body found in SUV
Ban called for in TX schools
Families lose appeal
To get a second moon
NYC subway joyride arrest
Man charged for threats
Collapse hazard recall
Hold campaign event in MI
Recalling 449K+ vehicles
Stein's ballot bid rejected
MS sheriff's office probe
Disney to stop using Slack
Vows to remain in race
Russia threatens retaliation
PGA welcomes LIV players
'Targeted strike' in Beirut
Raises settlement offer
$3B for battery projects
Brazil threatens daily fines
FTC on privacy controls
To visit US next week
COVID, Wuhan market link
Overdose deaths drop in US
Makes MLB history
Feedback